- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07604220
Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS) (EXODACS)
May 18, 2026 updated by: Andrew N Rosenbaum, Mayo Clinic
The purpose of this study is to develop a prospective cohort of patients with and without cardiac sarcoidosis as well as active and inactive disease to develop a prospective biobank from which exosome analysis of peripheral blood will derive unique biomarkers of disease activity in cardiac sarcoidosis.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
115
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Anna Pick
- Phone Number: 507-255-0630
- Email: pick.anna@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
Contact:
- Anna Pick
- Phone Number: 507-255-0630
- Email: pick.anna@mayo.edu
-
Contact:
- Andrew Rosenbaum, MD
- Phone Number: (507) 284-0783
- Email: Rosenbaum.Andrew@mayo.edu
-
Principal Investigator:
- Andrew Rosenbaum, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients referred to the Cardiac Sarcoid Clinic with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis.
Description
Inclusion Criteria
- Adults ≥18 years.
- Patients referred to the Cardiac Sarcoid Clinic with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis.
- Undergoing FDG-PET as part of standard care.
- Ability to provide informed consent.
Exclusion Criteria
• Inability to provide informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Cardiac Sarcoidosis Patients
Patients with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis.
|
Blood Samples will undergo exosome profiling using mass spectrometry and/or other discovery-based approaches
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of successful biomarker validations
Time Frame: Baseline
|
Biomarker validation will be defined as ability to discriminate active from inactive or quiescent disease as assessed by FDG-PET
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Andrew Rosenbaum, MD, Mayo Clinic
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 1, 2026
Primary Completion (Estimated)
July 1, 2028
Study Completion (Estimated)
July 1, 2028
Study Registration Dates
First Submitted
May 18, 2026
First Submitted That Met QC Criteria
May 18, 2026
First Posted (Actual)
May 22, 2026
Study Record Updates
Last Update Posted (Actual)
May 22, 2026
Last Update Submitted That Met QC Criteria
May 18, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 26-004241
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Sarcoidosis
-
Duke UniversityFoundation for Sarcoidosis ResearchRecruiting
-
Mayo ClinicCompleted
-
University of PennsylvaniaAdvanced Accelerator ApplicationsCompleted
-
Rigshospitalet, DenmarkWithdrawn
-
University of MichiganTerminated
-
Lars Christian GormsenCompleted
-
Ottawa Heart Institute Research CorporationWithdrawn
-
Heart Center Leipzig - University HospitalRecruiting
-
British Columbia Cancer AgencyApproved for marketing
-
University of Alabama at BirminghamTerminated
Clinical Trials on Exosome Analysis
-
Guangdong ProCapZoom Biosciences Co., Ltd.Not yet recruitingSjögren's Syndrome
-
Isfahan University of Medical SciencesTarbiat Modarres UniversityRecruitingCerebrovascular DisordersIran, Islamic Republic of
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownMyocardial InfarctionChina
-
Paracrine Therapeutics Dermatology Pte. Ltd.National University Hospital, SingaporeCompleted
-
Korea University Guro HospitalActive, not recruitingLung CancerKorea, Republic of
-
Isfahan University of Medical SciencesRecruiting
-
Yeditepe University HospitalCompleted
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsUnited States, Japan, South Korea
-
Isfahan University of Medical SciencesRecruiting
-
Fujian Medical UniversityNot yet recruiting